What were Gufic BioSciences Ltd's latest quarterly results?
Gufic BioSciences Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +175.0% (turning around (inflection up))
- Revenue Growth YoY: +22.9%
- Operating Margin: 19.0% (volatile)
Gufic BioSciences Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +15.1%Average4w Streak
In , Gufic BioSciences Ltd (Pharma - Formulators) is outperforming Nifty 500 with +15.1% relative strength. Fundamentals: Average. On a 4-week streak.
Gufic BioSciences Ltd Key Facts
- PE Ratio
- 56.5x
- Market Cap
- ₹3,627 Cr
- PAT Growth YoY
- +175%
- Revenue Growth YoY
- +23%
- OPM
- 19.0%
- RS vs Nifty 500
- +15.1%
Danger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
🏛️DII accumulation — stake up 1.2%
💰Trading 87% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+175%
Inflection Up
Revenue YoY
+23%
Stable
Operating Margin
19.0%
+600 bps YoY
PE Ratio
56.5
Current Price
₹362
Dividend Yield
0.03%
Fundamental Score
56/100
Average
3Y PAT CAGR
-14%
Market Cap
3.6K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Gufic BioSciences Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +23% | +8% | Stable |
| PAT (Net Profit) | +175% | -14% | Inflection Up |
| OPM | 19.0% | +600 bps | Volatile |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Gufic BioSciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Gufic BioSciences Ltd's profit growing or declining?
Gufic BioSciences Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +175.0% (latest quarter)
- PAT Growth QoQ: +83.3% (sequential)
- 3-Year PAT CAGR: -13.7%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Gufic BioSciences Ltd's revenue growth trend?
Gufic BioSciences Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +22.9%
- Revenue Growth QoQ: +9.1% (sequential)
- 3-Year Revenue CAGR: +8.2%
How is Gufic BioSciences Ltd's operating margin trending?
Gufic BioSciences Ltd's operating margin is volatile.
- Current OPM: 19.0%
- OPM Change YoY: +6.0% basis points
- OPM Change QoQ: +5.0% basis points
What is Gufic BioSciences Ltd's 3-year profit and revenue CAGR?
Gufic BioSciences Ltd's long-term compounding rates
- 3-Year Profit CAGR: -13.7%
- 3-Year Revenue CAGR: +8.2%
Is Gufic BioSciences Ltd's growth accelerating or decelerating?
Gufic BioSciences Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
- YoY Acceleration: +136.8% bps
- Sequential Acceleration: +79.4% bps
What is Gufic BioSciences Ltd's trailing twelve month (TTM) performance?
Gufic BioSciences Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹64 Cr
- TTM PAT Growth: -8.6% YoY
- TTM Revenue: ₹944 Cr
- TTM Revenue Growth: +15.1% YoY
- TTM Operating Margin: 16.1%
Is Gufic BioSciences Ltd overvalued or undervalued?
Gufic BioSciences Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 56.5x
- Price-to-Book: 5.5x
What is Gufic BioSciences Ltd's current PE ratio?
Gufic BioSciences Ltd's current PE ratio is 56.5x.
- Current PE: 56.5x
- Market Cap: 3.6K Cr
- Dividend Yield: 0.03%
How does Gufic BioSciences Ltd's valuation compare to its history?
Gufic BioSciences Ltd's current PE is 56.5x.
- Current PE: 56.5x
- Valuation Assessment: Significantly Overvalued
What is Gufic BioSciences Ltd's price-to-book ratio?
Gufic BioSciences Ltd's price-to-book ratio is 5.5x.
- Price-to-Book (P/B): 5.5x
- Book Value per Share: ₹66
- Current Price: ₹362
Is Gufic BioSciences Ltd a fundamentally strong company?
Gufic BioSciences Ltd is rated Average with a fundamental score of 55.96/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +22.9% (10% weight)
- PAT Growth YoY: +175.0% (10% weight)
- PAT Growth QoQ: +83.3% (10% weight)
- Margins stable (10% weight)
Is Gufic BioSciences Ltd debt free?
Gufic BioSciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹405 Cr
What is Gufic BioSciences Ltd's return on equity (ROE) and ROCE?
Gufic BioSciences Ltd's return ratios over recent years
- FY2025: ROCE 13.0%
- FY2026: ROCE 12.0%
Is Gufic BioSciences Ltd's cash flow positive?
Gufic BioSciences Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹45 Cr
- Free Cash Flow (FCF): ₹14 Cr
- CFO/PAT Ratio: 70% (adequate)
What is Gufic BioSciences Ltd's dividend yield?
Gufic BioSciences Ltd's current dividend yield is 0.03%.
- Dividend Yield: 0.03%
- Current Price: ₹362
Who holds Gufic BioSciences Ltd shares — promoters, FII, DII?
Gufic BioSciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 72.5%
- FII (Foreign): 0.4%
- DII (Domestic): 3.8%
- Public: 23.2%
Is promoter holding increasing or decreasing in Gufic BioSciences Ltd?
Gufic BioSciences Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 72.5% (Mar 2026)
- Previous Quarter: 72.5% (Dec 2025)
- Change: 0.00% (stable)
How long has Gufic BioSciences Ltd been outperforming Nifty 500?
Gufic BioSciences Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Gufic BioSciences Ltd a new momentum entry or an established outperformer?
Gufic BioSciences Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Is Gufic BioSciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Gufic BioSciences Ltd may be worth studying
- Earnings growing at +175.0% YoY
- Cash flow is positive — CFO ₹45 Cr
What is the investment thesis for Gufic BioSciences Ltd?
Gufic BioSciences Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +22.9% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Gufic BioSciences Ltd?
Gufic BioSciences Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.